KOD Stock Up 24% in 3 Months: Here's What You Need to Know

Key Takeaways Kodiak Sciences stock surges as late-stage programs for DR, wet AMD and macular edema drive momentum.KOD's tarcocimab, KSI-501 and KSI-101 are in pivotal studies with multiple top-line readouts through 2027.Kodiak Sciences bolstered its balance sheet via an 8.0M-share equity offering, extending its cash runway.Kodiak Sciences’ (KOD) shares have surged 24% over the past three months, driven by strong momentum around its late-stage pipeline and improving financial position, which have boosted in ...